Pliant Therapeutics, Inc. (NASDAQ:PLRX) Stock Now Rated “Hold” by Sell-Side Analysts

Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) have earned an average recommendation of “Hold” from the three ratings firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and one has given a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $3.00.

PLRX has been the topic of a number of recent research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Pliant Therapeutics in a report on Friday, July 17th. Wall Street Zen raised shares of Pliant Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, September 26th.

Get Pliant Therapeutics alerts:

Check Out Our Latest Analysis on PLRX

Institutional Trading of Pliant Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. ADAR1 Capital Management LLC bought a new position in Pliant Therapeutics during the 2nd quarter valued at approximately $6,281,000. Monaco Asset Management SAM purchased a new position in Pliant Therapeutics during the second quarter valued at $2,210,000. Renaissance Technologies LLC boosted its holdings in Pliant Therapeutics by 77.2% in the first quarter. Renaissance Technologies LLC now owns 1,852,842 shares of the company’s stock worth $2,335,000 after acquiring an additional 807,024 shares in the last quarter. BlackRock Inc. bought a new stake in Pliant Therapeutics in the second quarter worth $1,312,000. Finally, Eversept Partners LP boosted its holdings in Pliant Therapeutics by 5.9% in the first quarter. Eversept Partners LP now owns 891,425 shares of the company’s stock worth $1,123,000 after acquiring an additional 49,402 shares in the last quarter. Hedge funds and other institutional investors own 97.30% of the company’s stock.

Pliant Therapeutics Stock Performance

Shares of Pliant Therapeutics stock opened at $1.02 on Wednesday. The firm has a market capitalization of $63.16 million, a P/E ratio of -0.68 and a beta of 1.27. The business has a fifty day simple moving average of $1.10 and a two-hundred day simple moving average of $1.16. Pliant Therapeutics has a 12 month low of $0.97 and a 12 month high of $1.95.

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.02). Analysts predict that Pliant Therapeutics will post -1.42 earnings per share for the current year.

Pliant Therapeutics Company Profile

(Get Free Report)

Pliant Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for fibrotic diseases. The company uses its expertise in integrin biology to discover and develop medicines intended to address the underlying mechanisms that contribute to tissue scarring and organ dysfunction.

Pliant’s leading investigational product is bexotegrast, an oral, small-molecule inhibitor designed to selectively target the alphaVbeta6 and alphaVbeta1 integrins. The therapy has been studied in conditions including idiopathic pulmonary fibrosis, a progressive lung disease, and primary sclerosing cholangitis, a chronic liver disease.

Recommended Stories

• Five stocks we like better than Pliant Therapeutics
• 3 Stocks Chopped in Half: Why These Drops May Be Structural, Not a Dip
• Home Depot and Lowe’s Hit 52-Week Lows—But Analysts Aren’t Giving Up
• Utilities Are Bouncing Back—These 2 Giants Could Signal the Next Big Sector Rally
• Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes Next

Receive News & Ratings for Pliant Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pliant Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.